Biomarker study for patients getting first cancer treatment
Part of Cancer clinical trials.
This study looks at blood or tissue samples from people getting their first cancer treatment, either radiation or a combination of drugs, to find markers that could predict how well the treatment works. It might help future patients get more personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed solid tumor (not blood cancer).
- You are about to start your first cancer treatment.
- Your treatment is either radiation (with or without chemo) or a combination of immunotherapy and/or chemo drugs.
- You are willing to provide samples and follow study rules.
- You have not had chemo or immunotherapy in the last 5 years (if you're getting radiation), or you have not had radiation to the chest in the last 5 years (if you're getting drug therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks a “biomarker” (a measurable sign in your body, often from blood) in people who are being investigated for possible cancer in a specific body area. It may help researchers understand whether the marker can support or rule out cancer when no cancer has been confirmed yet.
This study collects blood (and other biospecimens) to look for immune and molecular markers that may help explain cancer risk or response to treatment. If you’re an adult whose provider thinks you could develop cancer, or who has confirmed/suspected cancer, you may be asked for samples and consent to help researchers.
This study uses advanced DNA testing on tumor samples to help match cancer treatments more precisely. It may help researchers learn which cancer changes are driving your tumor and how they relate to treatment choices.
This study measures “circulating tumor markers,” meaning substances from cancer that can show up in blood, to better understand how cancer is doing after treatment. You may join if you recently received cancer care at a participating center and meet basic study and follow-up requirements.
This study looks at how your body reacts to immunotherapy drugs (like PD-1 or CTLA-4 blockers) when given for the first time. It aims to predict side effects and help make treatment safer.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.